Vitrolife completes the acquisition of Igenomix and carries out a non-cash consideration issue

Report this content

On July 8, 2021, Vitrolife AB (publ) (“Vitrolife”) entered into a definitive agreement to acquire 100% of the shares in Igenomix S.L.[1] (“Igenomix”) from EQT and other shareholders (the “Transaction”). The conditions for the Transaction, including regulatory approvals such as merger control clearances, have been fulfilled and the acquisition of Igenomix is consequently completed.

The Extraordinary General Meeting resolved on October 20, 2021 to approve the non-cash consideration issue in accordance with the Board’s proposal. The Extraordinary General Meeting revolved to issue in total 17,251,312 new shares. As a result of the consideration issue the total number of shares in Vitrolife has increased from 118,195,878 to 135,447,190. The consideration issue entails a dilution of approximately 13 percent. In accordance with the resolution at the Extraordinary General Meeting, Vesa Koskinen will become a board member of Vitrolife AB.

Igenomix will be consolidated into Vitrolife’s financial statements as of December 1, 2021. To facilitate the consolidation, the report on operations 2021 will be postponed to February 16, 2022.

During the period January 1, 2021 – September 30, 2021, Igenomix revenue amounted to EUR 91.4 million (EUR 79.5 million excluding covid-19 related revenue). Adjusted EBITDA[2] during that period amounted to EUR 23.3 million.

For more information about the transaction, please refer to Vitrolife’s press release dated July 8, 2021. For more information about Igenomix, see

Gothenburg, November 30, 2021
Thomas Axelsson, CEO

[1] Mendel HoldCo S.L. and New Genetics S.L.

[2] Adjustments include transaction costs of EUR 9.9 million and other non-recurring costs of EUR 1.6 million.

Queries should be addressed to:
Thomas Axelsson, CEO, tel 46 31 721 80 01
Mikael Engblom, CFO, tel 46 31 721 80 14

This information is information that Vitrolife AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 7.10 pm CET on November 30, 2021.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.


Vitrolife is an international medical device Group. Vitrolife develops, produces and markets medical devices for assisted reproduction.

Vitrolife has approximately 400 employees and the company's products are sold in about 110 markets. The company is headquartered in Gothenburg, Sweden, and there are also offices in Australia, Belgium, China, Denmark, France, Germany, Italy, Japan, United Kingdom and USA. The Vitrolife share is listed on NASDAQ Stockholm.

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452. Tel: 46 31 721 80 00. Fax: 46 31 721 80 99. E-mail: Website:


Documents & Links